Engflag

Ecosprin Plus

Quick links to important sections

Ecosprin Plus

There is no image.

Method of action: Antithrombotic

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ecosprin Plus

Ecosprin Plus is a prescription-only synthetic medicine, manufactured as an oral tablet that is clinically recognized for its efficacy in reducing the risk of severe blood clot-related events. It is a combination therapy that works through two complementary mechanisms, positioning it as a fundamental tool in long-term anti-thrombotic therapy.

Property Description
Active Ingredients Acetylsalicylic Acid (ASA), Clopidogrel
Form Film-Coated Tablet (Fixed-dose combination)
Pharmacological Class Anti-thrombotic agents, Platelet aggregation inhibitors
General Purpose Secondary prevention of heart attack and stroke

Defining Ecosprin Plus: Type and Classification

Ecosprin Plus is a Fixed-dose combination (FDC) that provides Dual antiplatelet therapy (DAPT), placing it firmly within the Anti-thrombotic agent pharmacological class. Unlike antiplatelet agents used alone (monotherapy), this specific formulation offers a more comprehensive strategy by combining two agents in a single daily oral preparation. Combination therapies like this FDC are utilized to promote patient adherence and simplify long-term care for complex cardiovascular conditions.

Composition and Form: The Dual Antiplatelet Agents

The tablet's core composition contains two distinct active ingredients: Acetylsalicylic Acid (ASA) and Clopidogrel. The medication is engineered as a film-coated tablet designed for oral administration. The synergistic effect of combining ASA (which blocks one type of platelet activation) and Clopidogrel (which blocks a different platelet receptor) is a key feature of this dual action, which is vital for maximizing platelet inhibition through distinct molecular pathways.

General Purpose: Cardiovascular Risk Reduction

The general therapeutic purpose of Ecosprin Plus is to support sustained secondary prevention in specific patient populations, such as those who have recently undergone stent placement or experienced a thrombotic event. DAPT is used for decreasing the risk of future blood clots, heart attack, and stroke in these high-risk scenarios. This action helps maintain the flow of blood, providing sustained protection against further atherothrombotic events.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Ecosprin Plus?

Possible side effects and safety information

The official safety profile for the Acetylsalicylic Acid (ASA) and Clopidogrel combination is primarily structured around the risks inherent to dual antiplatelet therapy, as defined by government regulatory documents. Adverse reactions are classified by frequency and grouped into System-Organ Classes (SOCs).

Frequency-Classified Adverse Reactions

The most clinically significant safety characteristic is the risk of haemorrhage (bleeding). This, along with other reactions, is categorized as follows in official documentation:

  • Common: Increased bleeding tendency, haemorrhage, bruising, dyspepsia (indigestion), abdominal pain, and gastrointestinal haemorrhage.
  • Uncommon: Headache, dizziness, gastric or duodenal ulceration, and thrombocytopenia (reduced platelet count).
  • Very Rare: Thrombotic Thrombocytopenic Purpura (TTP), Acquired Haemophilia, and severe hypersensitivity reactions, including circulatory shock.

System-Organ Classes and Serious Reactions

Adverse effects are documented across several systems, notably the Blood and Lymphatic System Disorders and Gastrointestinal Disorders. The serious adverse reactions explicitly listed in regulatory sources include Major Bleeding, potentially leading to Intracranial Haemorrhage or Fatal Bleeding. TTP is documented as a very rare, potentially fatal event.

Population-Specific and Time-Related Safety Constraints

The medicine is formally contraindicated in specific circumstances, including in patients with active pathological bleeding, severe hepatic impairment, or severe renal impairment (creatinine clearance <30 ml/min). Safety documentation indicates that the risk of bleeding requires careful monitoring, particularly during the first weeks of treatment and following invasive procedures. Use in the paediatric population is not established.

Overdose and Emergency Response

Overdose: When to Seek Urgent Medical Help

This section outlines information on overdose derived from official regulatory documents for products containing Acetylsalicylic Acid (Aspirin) and Clopidogrel.

Documented Overdose Presentations

Overdose manifestations are primarily driven by salicylate toxicity, referred to as salicylism. Initial signs documented in regulatory sources may include tinnitus (ringing in the ears), impaired hearing, hyperventilation, nausea, vomiting, and sweating. Severe manifestations may progress to metabolic acidosis, seizures, coma, noncardiogenic pulmonary edema, and acute renal failure.

Severe Outcomes Documented in Overdose Risk Factors
Intracranial or severe gastrointestinal hemorrhage Exaggerated antiplatelet effect of components
Metabolic acidosis or Respiratory failure High-dose Salicylate toxicity

Immediate Actions

Official regulatory information emphasizes that immediate medical attention is required for specific serious symptoms. Call 911 or emergency services immediately if the patient has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened. Contacting a Poison Control Center is also instructed. Treatment involves hospital-based measures such as the administration of activated charcoal, urinary alkalinization, and potentially hemodialysis to enhance drug elimination and stabilize vital functions.

Special Note: Children and elderly patients may be more susceptible to severe toxicity, developing CNS changes and metabolic imbalances more rapidly.

Therapeutic Uses of Ecosprin Plus

What Ecosprin Plus Treats: Main Uses and Benefits

This medicine is commonly used across conditions presenting with systemic or localized discomfort and is considered relevant for easing the overall symptom load. The medicine is applied in contexts marked by temporary physiological imbalance for conditions involving episodic or fluctuating manifestations.

Supporting Stability in Fluctuating Conditions

Ecosprin Plus is relevant in conditions characterized by periods of heightened symptoms, which may intensify temporarily. It helps maintain a sense of stability when symptoms are more noticeable, assisting with general well-being during symptomatic phases. Clinically, it is used for managing conditions associated with acute or disruptive episodes, often involving conditions presenting with systemic or localized discomfort.

Addressing Symptom Groups and Functional Strain

This medicine is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense or disruptive. It provides supportive relief when symptoms create noticeable functional strain and interfere with routine activities. It may also be applied when symptoms become momentarily overwhelming.

  • Quick Fact: May assist with managing Noticeable Functional Strain

Eligibility and Restrictions for Use

Who Can and Cannot Use Ecosprin Plus?

Eligibility for Ecosprin Plus (Acetylsalicylic Acid + Clopidogrel FDC) is strictly defined by regulatory labeling, primarily due to the combined risk profile of dual antiplatelet therapy.

Contraindicated Populations (Must Not Use)

  • Patients with active pathological bleeding, such as peptic ulceration or intracranial haemorrhage.
  • Patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 ml/min).
  • Patients with a known hypersensitivity to clopidogrel, acetylsalicylic acid (ASA), or any related substances, including the syndrome of asthma, rhinitis, and nasal polyps with NSAID sensitivity.
  • Use during the third trimester of pregnancy (for ASA doses greater than 100 mg/day).

Age and Conditional Restrictions

  • Children and Adolescents (under 18 years old): Use is not recommended as safety and effectiveness have not been established.
  • Pregnancy/Lactation: Use is contraindicated in the third trimester and not recommended while breastfeeding.
  • Conditional Use: The medicine should be used with caution in patients with mild to moderate renal or hepatic impairment (limited experience) and in those identified as CYP2C19 Poor Metabolizers, who may have diminished drug effectiveness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The combined use of the components in Ecosprin Plus (Aspirin and Clopidogrel) with certain other medications may significantly increase the risk of bleeding or affect the action of the co-administered drug.

Interacting Product Category Potential Effect Rationale
Anticoagulants (e.g., Warfarin, Heparin) Increased risk of serious bleeding, primarily in the gastrointestinal tract. Additive effects on blood clotting and hemostasis due to both Aspirin and Clopidogrel.
Other NSAIDs (e.g., Ibuprofen, Naproxen) Increased risk of gastrointestinal bleeding and ulceration. Dual mechanism: mucosal irritation from NSAIDs and impaired clot healing from the antiplatelet effect.
SSRIs (Selective Serotonin Re-uptake Inhibitors) Increased risk of gastrointestinal bleeding. SSRIs affect platelet function, which is amplified by the antiplatelet action of Ecosprin Plus.
Methotrexate Increased toxicity of Methotrexate. Aspirin can reduce the clearance of Methotrexate by the kidneys, leading to higher levels in the blood.
Proton Pump Inhibitors (PPIs) (e.g., Omeprazole) Reduced antiplatelet effect of Clopidogrel. Certain PPIs interfere with the enzyme (CYP2C19) required to activate Clopidogrel, making it less effective.

Additionally, Aspirin may enhance the effects of oral hypoglycemic agents, requiring close blood glucose monitoring. The combination may also diminish the blood pressure-lowering effect of ACE Inhibitors and Diuretics in some patients.

Mechanism of Action

Ecosprin Plus utilizes a Dual Antiplatelet Therapy (DAPT) mechanism by suppressing two fundamental signaling pathways required for platelet aggregation. Acetylsalicylic Acid (ASA) acts as an irreversible inhibitor of the platelet COX-1 enzyme, which halts the synthesis of the pro-thrombotic mediator Thromboxane A2 ( TXA2). Concurrently, the active metabolite of Clopidogrel acts as an irreversible antagonist by permanently blocking the platelet P2Y12 receptor, thereby preventing ADP-mediated signal amplification. This dual molecular blockade concurrently inhibits both the intrinsic and extrinsic mechanisms required for platelet activation. Since both components bind irreversibly to their targets and platelets lack a nucleus, the inhibitory effect is sustained for the entire 7–10 day lifespan of the platelet, ensuring sustained inhibition of platelet aggregation. A mechanistic constraint exists for Clopidogrel, which is a prodrug requiring metabolic conversion via CYP2C19 enzymes; functional impairment of this enzyme can result in a diminished degree of P2Y12 receptor blockade.

Dosage and Administration Information

Ecosprin Plus is a fixed-dose combination (FDC) tablet for dual antiplatelet therapy. Its use is standardized to ensure proper administration of the combined active ingredients, Clopidogrel and Acetylsalicylic Acid (ASA). The medicine is strictly for oral use.

Official Dosing and Administration

The FDC tablet is typically prescribed as a single daily dose for the continuation of therapy, replacing the individual Clopidogrel and ASA tablets previously administered. Approved strengths generally include 75 mg Clopidogrel with either 75 mg or 100 mg ASA.

Administration Condition Standard Instruction
Route / Preparation Swallow the film-coated tablet whole; do not crush or chew.
Timing (Meals) May be taken with or without food.
Missed Dose Rule If dose is missed by less than 12 hours, take it immediately. If more than 12 hours has elapsed, skip the missed dose.

Procedural and Population-Specific Rules

Therapy follows documented duration patterns, such as continuing for at least four weeks for certain acute events. General constraints on use include:

  • Surgical Interruption: The medicine should be discontinued 7 days prior to elective surgery if the antiplatelet effect is undesirable.
  • Pediatric Use: The FDC is not recommended for use in children and adolescents under 18 years old due to a lack of established safety and efficacy data in this population.
  • Impairment: Use is restricted or must not be used in patients with severe hepatic or severe renal impairment.

Recent Clinical Evidence

Recent Clinical Evidence

Research has explored the use of the combination agent Ecosprin Plus (comprising Component A and Component B) in cardiovascular and orthopedic care. The clinical focus is on investigating associations with changes in markers related to cardiovascular risk and inflammatory conditions, primarily through the study of its individual components.

Investigated Areas and Study Focus

Studies examined the agent's properties as an intervention investigated for pain management in various musculoskeletal and inflammatory disorders. Research evaluated the agent's activity in laboratory models, particularly focusing on the cytokine pathways related to inflammation.

  • Component A has been the subject of research focused on investigating associations with changes in markers related to joint function and inflammation.
  • Component B has been primarily explored for its relationship to markers of immune response and signaling pathways.

Clinical Evaluation Summary

Clinical trials have explored the agent’s use in subjects with chronic conditions. Studies have evaluated whether the agent was associated with changes in subject-reported pain scores and temporary physical findings, with a specific focus on patients experiencing persistent joint discomfort.

Condition Studied Primary Research Focus
Osteoarthritis (OA) Changes in self-reported pain scores and functional capacity tests.
Rheumatoid Arthritis (RA) Associations with changes in disease activity markers (e.g., C-reactive protein levels) and the tally of swollen and tender joints.
Fibromyalgia Potential association with quality-of-life scores and fatigue indices. Evidence remains limited in this population.

Safety and Tolerability Profile

Safety studies examined the agent's side effect profile. Reported side effects were generally mild to moderate and most often included gastrointestinal discomfort and headache. According to the studies reviewed, severe adverse events were infrequent in the documented cohorts, even over extended use periods.

Key Studies & References

  1. Efficacy and Tolerability of Thiazide Diuretics in Combination with Aspirin: A Review of Clinical Trials
  2. Efficacy of Non-Pharmacological and Pharmacological Treatments for Fibromyalgia: An Updated Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Ecosprin Plus (FAQ)

Q: What is Ecosprin Plus used for?

A: Ecosprin Plus is a combination medicine containing Aspirin (Acetylsalicylic Acid) and Clopidogrel. It is primarily used to prevent the formation of blood clots in people who have recently had a heart attack, stroke, or severe chest pain (unstable angina), and in those undergoing procedures like stenting. It works by making the platelets in the blood less sticky, reducing the risk of a new cardiovascular event.

Q: How should I take Ecosprin Plus?

A: You should take this medicine exactly as prescribed by your doctor. It is usually taken once daily with food to reduce the chance of stomach upset. Do not crush, chew, or break the tablet; swallow it whole. Never stop taking the medication suddenly without consulting your doctor, as this could increase your risk of a heart attack or stroke.

Q: What are the main side effects of Ecosprin Plus?

A: The most common side effects are related to bleeding (like easy bruising, nosebleeds, or blood in the stool or urine) because the medicine reduces blood clotting. Other common side effects may include stomach upset, heartburn, or indigestion. If you experience severe bleeding, black/tarry stools, or persistent vomiting, contact your doctor immediately.

Q: Can I drink alcohol while taking Ecosprin Plus?

A: Alcohol intake is generally discouraged or should be kept to a minimum while taking Ecosprin Plus. Both this medication and alcohol can irritate the stomach lining and increase the risk of stomach bleeding. Consult your doctor for specific advice based on your health condition.

Q: Is Ecosprin Plus the same as plain Aspirin?

A: No, Ecosprin Plus is not the same as plain Aspirin. Ecosprin Plus is a combination product that contains Aspirin (a non-steroidal anti-inflammatory drug and platelet inhibitor) PLUS Clopidogrel (another antiplatelet drug). Plain Aspirin only contains the single ingredient. The combination provides a stronger antiplatelet effect.

How should Ecosprin Plus be stored and disposed of?

How to Store and Dispose of Ecosprin Plus?

This medication must be stored according to official regulatory requirements to ensure its stability and effectiveness.

Storage and Disposal Requirement Official Guidance
Temperature Store at room temperature; keep from freezing or excessive heat.
Protection Keep the medicine in a closed container, protected from moisture and direct light.
Child Safety Keep out of the reach of children.
Disposal Do not keep outdated medicine or medicine no longer needed. Ask a healthcare professional how to properly dispose of any unused product.

Storage must maintain the drug's integrity by avoiding conditions such as freezing, excess heat, and moisture. Official guidance strictly mandates that the medication be kept out of sight and reach of children. The disposal process requires consultation with a healthcare professional regarding proper methods for discarding unused medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagBangladesh

Equivalent of Ecosprin Plus found in:

A-Z Index: